| Name | Walgreens #10220 |
|---|---|
| Organization Name | Walgreen Co |
| Location | 520 Broadway Ave, Bedford, Ohio 44146 |
| Type | Pharmacy |
| Phone | (440) 232-6500 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Professor Patrick Johnston is one of a number of pioneering scientists exploring how intimate genetic knowledge from individual tumours could help doctors predict which treatments will benefit their patients best. Major trials of this approach – which has shown considerable success in the lab – are needed to test its full predictive potential.
According to new research on epilepsy, zebrafish have certainly earned their stripes. Results of a study in Nature Communications suggest that zebrafish carrying a specific mutation may help researchers discover treatments for Dravet syndrome (DS), a severe form of pediatric epilepsy that results in drug-resistant seizures and developmental delays.
Researchers from Caris Life Sciences and Fox Chase Cancer Center – Temple Health announced the presentation of two studies revealing the potential for exploring new therapeutic options for triple-negative breast cancer (TNBC) at the 2015 San Antonio Breast Cancer Symposium.
ALLOZYNE, Inc. announced today, the completion of its first Phase IA clinical trial in healthy individuals for AZ01, a PEGylated form of human interferon beta-1b which is being developed for the treatment of relapsing remitting multiple sclerosis. The objectives of the Phase IA trial were to assess safety and tolerability profile in addition to defining its pharmacological properties.
› Verified 4 days ago
| NPI Number | 1033490099 |
| Organization Name | WALGREENS |
| Type | Pharmacy |
| Address | 520 Broadway Ave, Bedford, OH 44146 |
| Phone Number | 440-232-6500 |
News Archive
Professor Patrick Johnston is one of a number of pioneering scientists exploring how intimate genetic knowledge from individual tumours could help doctors predict which treatments will benefit their patients best. Major trials of this approach – which has shown considerable success in the lab – are needed to test its full predictive potential.
According to new research on epilepsy, zebrafish have certainly earned their stripes. Results of a study in Nature Communications suggest that zebrafish carrying a specific mutation may help researchers discover treatments for Dravet syndrome (DS), a severe form of pediatric epilepsy that results in drug-resistant seizures and developmental delays.
Researchers from Caris Life Sciences and Fox Chase Cancer Center – Temple Health announced the presentation of two studies revealing the potential for exploring new therapeutic options for triple-negative breast cancer (TNBC) at the 2015 San Antonio Breast Cancer Symposium.
ALLOZYNE, Inc. announced today, the completion of its first Phase IA clinical trial in healthy individuals for AZ01, a PEGylated form of human interferon beta-1b which is being developed for the treatment of relapsing remitting multiple sclerosis. The objectives of the Phase IA trial were to assess safety and tolerability profile in addition to defining its pharmacological properties.
› Verified 4 days ago
| NPI Number | 1518972579 |
| Organization Name | WALGREEN CO |
| Doing Business As | WALGREENS #10220 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 520 Broadway Ave, Bedford, OH 44146 |
| Phone Number | 440-232-6500 |
News Archive
Professor Patrick Johnston is one of a number of pioneering scientists exploring how intimate genetic knowledge from individual tumours could help doctors predict which treatments will benefit their patients best. Major trials of this approach – which has shown considerable success in the lab – are needed to test its full predictive potential.
According to new research on epilepsy, zebrafish have certainly earned their stripes. Results of a study in Nature Communications suggest that zebrafish carrying a specific mutation may help researchers discover treatments for Dravet syndrome (DS), a severe form of pediatric epilepsy that results in drug-resistant seizures and developmental delays.
Researchers from Caris Life Sciences and Fox Chase Cancer Center – Temple Health announced the presentation of two studies revealing the potential for exploring new therapeutic options for triple-negative breast cancer (TNBC) at the 2015 San Antonio Breast Cancer Symposium.
ALLOZYNE, Inc. announced today, the completion of its first Phase IA clinical trial in healthy individuals for AZ01, a PEGylated form of human interferon beta-1b which is being developed for the treatment of relapsing remitting multiple sclerosis. The objectives of the Phase IA trial were to assess safety and tolerability profile in addition to defining its pharmacological properties.
› Verified 4 days ago
News Archive
Professor Patrick Johnston is one of a number of pioneering scientists exploring how intimate genetic knowledge from individual tumours could help doctors predict which treatments will benefit their patients best. Major trials of this approach – which has shown considerable success in the lab – are needed to test its full predictive potential.
According to new research on epilepsy, zebrafish have certainly earned their stripes. Results of a study in Nature Communications suggest that zebrafish carrying a specific mutation may help researchers discover treatments for Dravet syndrome (DS), a severe form of pediatric epilepsy that results in drug-resistant seizures and developmental delays.
Researchers from Caris Life Sciences and Fox Chase Cancer Center – Temple Health announced the presentation of two studies revealing the potential for exploring new therapeutic options for triple-negative breast cancer (TNBC) at the 2015 San Antonio Breast Cancer Symposium.
ALLOZYNE, Inc. announced today, the completion of its first Phase IA clinical trial in healthy individuals for AZ01, a PEGylated form of human interferon beta-1b which is being developed for the treatment of relapsing remitting multiple sclerosis. The objectives of the Phase IA trial were to assess safety and tolerability profile in addition to defining its pharmacological properties.
› Verified 4 days ago
Cvs Pharmacy # 04330 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 140 Solon Road, Bedford, Ohio 44146 Phone: (440) 439-5766 | |
Giant Eagle Pharmacy #0209 Type: Pharmacy Location: 900 Northfield Rd, Bedford, Ohio 44146 Phone: (440) 439-1416 | |
Isalon Plus Llc Type: Medicare Supplier Location: 18 Columbus St, Bedford, Ohio 44146 Phone: (440) 232-8191 | |
Marlen Mfg. & Development Co Type: Durable Medical Equipment & Medical Supplies Supplier Location: 5150 Richmond Rd, Bedford, Ohio 44146 Phone: (216) 292-7060 |